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Cyclin A is associated with an unfavourable outcome in
patients with non-small.cell lung carcinomas
M Volm, R Koomagi, J Mattern and G Stammier
German Cancer Research Centre, Department of Oncological Diagnostics and Therapy, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
Summary Specimens of formalin-fixed, paraffin-embedded non-small-cell lung carcinomas (NSCLCs; n = 187) were analysed immuno-
histochemically for expression of cyclin A. The analysis was intended to determine whether cyclin A has additional prognostic value for
predicting patients' survival and drug response. Of the 187 NSCLCs, 141 cases (75%) showed expression of cyclin A. Patients with cyclin
A-positive carcinomas had significantly shorter median survival times than patients with cyclin A-negative carcinomas (79 vs 129 weeks,
P= 0.045). Similar results were obtained with more homogeneous groups of patients: patients with only T3 tumours, patients with epidermoid
carcinomas and patients with lymph node involvement. The clinical parameters (age, stage, histology, extent of tumour size, lymph node
involvement) had no influence on expression of cyclin A. A direct correlation between cyclin A and the proportion of S-phase cells (P = 0.08)
and an inverse relationship between cyclin A and the proportion of G0/Gl-phase cells (P = 0.04) were found. Furthermore, a significant
correlation between the expression of cyclin A and the response of NSCLC to doxorubicin in vitro was detected (P= 0.026).
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Estimating theproliferative activity oftumours is important forthe
management and prognosis oftumour patients. Using flow cytom-
etry in an earlier study, we found that patients with non-small-cell
lung carcinomas (NSCLC) who had tumours with ahighprolifera-
tive activity (high proportion of S and G2/M cells) had signifi-
cantly shorter survival times than patients with tumours having a
low proliferative activity (Volm et al, 1985, 1988). Patients with
ovarian carcinomas having high proliferative activity also died
earlier than patients with carcinomas having low proliferative
activity (Volm et al, 1985). However, there were various limita-
tions in the earlier assays. A disadvantage of flow cytometry was
that such analyses required fresh tissues and single-cell suspen-
sions. In our earlier studies, cell cycle analyses were also not
possible in all tumour samples because DNA stemlines over-
lapped. In contrast, immunohistochemical analysis applies to
small tumour specimens and to archival material.
Cell cycle progression is controlled by protein complexes
composed of cyclins and cyclin-dependent kinases (Cdks); the
cyclins act as regulatory molecules and the Cdks as catalytic
subunits (Cordon-Cardo, 1995). The periodic appearance of the
different cyclins in distinct phases of the cell cycle suggests that
these proteins can also be used as markers for tissue proliferation
(Dutta et al, 1995).
In the present investigation, we analysed formalin-fixed,
paraffin-embedded tumour sections frompatients with NSCLC for
expression of cyclin A. Using immunohistochemistry, we deter-
mined the relevance of cyclin A for patient survival and drug
response in vitro.
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MATERIALS AND METHODS
Patients and tumours
One hundred and eighty-seven patients with previously untreated
non-small-cell lung carcinomas (NSCLC) were admitted into this
study. All patients were surgically treated in the Chest Hospital
Heidelberg-Rohrbach. The minimum follow-up time is 5 years.
The morphological classification ofthe carcinomas was conducted
according to the WHO study (1981). Tumour classifications were
carried out by two pathologists. Of the 187 tumours, 107 were
epidermoid carcinomas, 50 adenocarcinomas and 30 large-cell
carcinomas. All patients were staged at the time of their surgery
according to the guidelines of the American Joint Committee on
Cancer (Carr and Mountain, 1977). Thirty-seven patients had
stage I, 17 had stage II and 133 had stage III tumours. The patients
(167 men, 20 women) ranged in age from 28 to 76 years (average
age 58 years). Seventy-one patients did not have lymph node
involvement, while 115 patients had lymph node involvement (one
patient could not be classified). One hundred and twenty-seven
patients were treated only by surgical procedures, 23 patients were
additionally treated with cytotoxic drugs and 37 patients (mainly
epidermoid carcinomas) were treated with irradiation. The addi-
tional radiation treatment and chemotherapy had no significant
effect on patient survival time. Follow-up data were obtained from
hospital charts and by corresponding with the referring physicians.
The survival times were determined from the day of surgery. Only
patients who were alive at least 4 weeks after surgery were
included in this investigation. No patients were lost to follow-up.
Immunohistochemistry
The previously described biotin-streptavidin method was used to
detect cyclin A (Volm et al, 1993). Staining for the cyclin A
protein was carried out using a rabbit polyclonal antibody (cyclin
A, H-432; Santa Cruz Biotechnology, Heidelberg, Germany)
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corresponding to amino acids 1-432 and representing full length
cyclin A of human origin. The antibody is specific for cyclin A
p60 and is non-cross-reactive with other cyclins, according to the
manufacturer. Western blotting showed no cross-reaction with
other proteins (Hartsough et al, 1996). Formalin-fixed and
paraffin-embedded tumour sections were deparaffinized. After
preincubation with hydrogen peroxide (0.3%), saponin (0.05%),
unlabelled streptavidin and non-immunized normal serum (1:10,
15 min), the primary antibody (dilution 1:50) was applied for 16 h
at 4°C in a moist chamber. Following a washing with phosphate-
buffered saline (3x), the sections were incubated for 45 min at
room temperature using biotinylated goat anti-rabbit Ig (1:50)
as a secondary antibody (with 5% normal human serum).
Thereafter, the streptavidin biotinylated peroxidase complex
(Amersham, Braunschweig, Germany; dilution 1:100, 15 min)
was added. Subsequent to washing (3x) with buffered saline and
incubation in 0.5% Triton X-100 (30 s), the peroxidase activity
was visualized with 3-amino-9-ethylcarbazole (15 min).
Counterstaining was performed with haematoxylin. Negative
controls were carried out by omitting the primary antibody and by
substituting an irrelevant antibody for the primary antibody.
Positive controls were performed by using high proliferating cells
from logarithmic growth phases. The immunohistochemical
staining was analysed according to a scoring method that we have
previously validated in a series of animal and human cell lines and
human solid tumours.
Three observers independently evaluated the results from the
immunohistochemical staining without having any prior knowl-
edge ofeach patient's clinical data. The evaluations agreed in 90%
of the samples. The other specimens (10%) were re-evaluated and
then classified according to the classification given most
frequently by the observers. To evaluate protein expression, a
score corresponding to the sum of (a) the percentage of positive
cells (0 = 0% immunopositive cells; 1 = < 25% positive cells; 2 =
26-50% positive cells; and 3 = > 50% positive cells) and (b) the
staining intensity (0 = negative; 1 = weak; 2 = moderate; 3 = high)
was established. The sum of a+b attained a maximum score at 6.
The cells were graded as negative when there was complete
absence of staining (score 0). The scores 2-6 were classified as
positive. In this study, we compared the group ofpositive tumours
(composed of all positive subgroups) with the group of negative
tumours because no significant relationships exist between
survival and the different degrees ofpositive staining.
Cell cycle analysis (flow cytometry)
Flow cytometry analysis was carried out using an ICP-22 (Phywe,
Gottingen, Germany). A mixture ofpropidium iodide (10gg ml-')
and 4'-6-diamidino-2-phenylindole (DAPI, 2 gg ml-' of each in
0.15 M Tris-HCI buffer) was applied simultaneously with RNAase
(1 mg ml-') after methanol fixation and protease digestion (solu-
tion of0.5% pepsin). For fluorescence excitation and detection, we
used UB1IBG 38 and FT 450/KV 540 filters (Schott, Mainz,
Gdrmany). Peripheral blood leucocytes from healthy donors were
used as a calibration standard for DNA diploidy. Parallel measure-
ments, both including and omitting the standard, were performed.
The identity of this internal standard with normal DNA stemlines
in the specimens could be confirmed. The cell cycle analysis was
performed using integrated Gaussian fittings. A computerized
subtraction of exponentially decreasing corrections beginning
with the peak of cellular debris was included in the evaluation
programme. The cell cycle analysis was omitted in cases showing
interspersed cell populations (35%).
Detection of doxorubicin resistance
The short-term test for predicting resistance to doxorubicin has
been described previously (Group for Sensitivity Testing of
Tumours, KSST, 1981). The basic principle of the short-term test
for predicting resistance is measuring the changes in the incorpo-
ration ofradioactive nucleic acid precursors into tumour cells after
adding cytostatics. Only fresh tumour specimens were processed.
The biological variability within the individual samples was mini-
mized by using large tumour segments. Adjacent sections of the
specimens were used for additional histological examinations.
Tumour material was freed from fat and necrotic parts. Solid
tumours were first mechanically disrupted and filtered through
gauze, then the cells were sedimented and subsequently resus-
pended at a defined cell density (5 x 105 cells ml-'). Drugs were
dissolved in TCM-199 and were usually tested over a four-log
concentration range. After incubation for 2 h, the radioactive
nucleic precursor was added ([3H]uridine, 2.5 ,Ci ml') and the
incubation was continued for 1 h. Then, 100-gl aliquots were
pipetted from each test tube onto filter paper discs and dried in a
stream of warm air. The non-incorporated radioactivity was
extracted with ice-cold trichloroacetic acid. The filters were then
washed in ethanol-ether and the incorporated radioactivity deter-
mined by liquid scintillation counting. Uptake values for the
individual concentrations were expressed as percentages of the
controls. Tumours were defined as being sensitive or resistant
depending upon prior clinical correlations (Group for Sensitivity
Testing of Tumours, KSST, 1981). The cut-off point chosen
was 65% of the control for a doxorubicin concentration of
10-2 mg ml'. After adding doxorubicin, the test results were
assessed relative to the control samples. Of our group of patients,
134 cases were analysed by the short-term test.
Statistical analysis
Life table analyses according to Kaplan and Meier were performed
for the overall survival rate. The groups were compared by log-
rank tests and, based on those, relative risks were calculated (RR).
The correlations between clinical and molecular parameters were
evaluated statistically by using Fisher's exact test (Fleiss, 1973).
The latter was used as a statistical hypothesis test for the presence
or absence of an association between two factors. A P-value of
< 0.05 was considered to be significant.
Figure 1 Immunohistochemical staining of cyclin A in a human lung tumour
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Table 1 Median survival times (MST) of patients with NSCLC subdivided according to the expression of cyclin A
Clinical characteristics Cyclin A No. of patients MST (weeks) P-value RR
Total Negative 46 129 0.045 1.0
Positive 141 79 1.5
Stage
l/ll Negative 18 144 NS (0.82) -
Positive 36 111
ill Negative 28 102 0.044 1.0
Positive 105 58 1.7
Extent of tumour
T 1/2 Negative 20 184 NS (0.31) 1.0
Positive 47 95 1.4
T3 Negative 26 93 NS (0.13) 1.0
Positive 94 60 1.5
Lymph node involvement
Negative Negative 18 139 NS (0.94) -
Positive 53 141
Positive Negative 28 93 0.021 1.0
Positive 87 47 1.9
Histology
Epidermoid carcinoma Negative 29 > 260 0.028 1.0
Positive 78 87 1.9
Adenocarcinoma Negative 10 129 NS (0.39) 1.0
Positive 40 56 1.4
Large-cell carcinoma Negative 7 78 NS (0.61) -
Positive 23 80
RR, relative risk.
RESULTS
Formalin-fixed, paraffin-embedded specimens from 187 non-
small-cell lung carcinomas (NSCLC) of previously untreated
patients were analysed immunohistochemically for the expression
ofcyclin A. Figure 1 shows a representative expression pattern of
cyclin A, which reveals nuclear immunoreactivity. The analysis
was intended to determine whether cyclin A has additional prog-
nostic value for predicting patient survival and drug response. Of
the 187 analysed samples, expression of cyclin A was found in
141 cases (75%), while in 46 cases (25%) expression was not
detectable. Age, stage, histology, extent of tumour size and lymph
node involvement had no influence on cyclin A expression (data
not shown).
Extent and location of the primary tumour (T) and lymph node
involvement in patients with NSCLC are well-known prognostic
factors for survival. Their prognostic significance is also clearly
established in our study (data not shown). On the other hand,
histology did not have significant prognostic value.
Patients with cyclin A-positive carcinomas had significantly
shorter median survival times than patients with cyclin A-negative
carcinomas (79 vs 129 weeks; P = 0.045). The estimated relative
risk in the cyclin A-positive group ofpatients was 1.5 (Table 1). To
exclude the influence or possible introduction of a bias into the
analysis, we furtheranalysed theexpression ofcyclin A in stageI, II
and III tumours, with respect to tumour extent, lymph node involve-
ment and histology. With this more homogeneous group ofpatients
we obtained similar results. The estimated relative risk for patients
with stage III tumours was 1.7, for patients with lymph node
involvement and for patients with epidermoid carcinomas 1.9.
Figure 2 shows the Kaplan-Meier estimates for all patients. It is
clearly shown that patients with cyclin A-positive carcinomas had
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Figure 2 Survival curves of patients (Kaplan-Meier estimates) having non-
small-cell lung carcinomas with and without cyclin A expression (n = 187)
significantly shorter survival times than patients whose carci-
nomas did not exhibit cyclin A expression.
Furthermore, we analysed whether there is an association
between cyclin A expression as determined by immunohistochem-
istry and the distribution of cell cycle phases measured by flow
cytometry (Table 2). A directcorrelation between the proportion of
S-phase cells and the expression of cyclin A could be detected in
the carcinomas (P = 0.08). An inverse relationship of significance
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Table 2 Relationship between the expression of cyclin A determined by
immunohistochemistry and cell cycle phases measured by flow cytometry
(n = 97)
Cell cycle phasesa Cyclin A P-value
Negative Positive
n(%) n(%)
GO/G, phases
.78% 11 (21) 41 (79) 0.04
> 78% 18 (40) 27 (60)
S-phases
.8% 14 (41) 20 (59) 0.08
> 8% 15 (24) 48 (76)
aCut-off points determined by critlevel procedure (Abel et al, 1984).
Table 3 Relationship between cyclin A expression and the response to
doxorubicin in vitro (n = 134)
Cyclin A P-value
Negative Positive
n (%) n (%)
Sensitive 11 (27) 30 (73) 0.026
Resistant 44 (47) 49 (53)
exists between the proportion of GO/G1-phase cells and cyclin A
expression (P = 0.04).
Finally, the expression of cyclin A was compared with the
response of NSCLC to doxorubicin measured in vitro. The basic
principle of the short-term test for detecting the response was to
measure the changes in the incorporation of radioactive nucleic
acid precursors into tumour cells after adding doxorubicin. Using
this test system, we found that, ofthe 134 analysed carcinomas, 41
were sensitive (31%) and 93 were resistant (69%). Table 3 shows
that cyclin A expression is significantly linked to the response to
doxorubicin in vitro (P = 0.026). The cyclin A-negative tumours
(i.e. tumours with low proliferative activity) were more frequently
resistant and the cyclin A-positive tumours were more frequently
sensitive.
DISCUSSION
Cyclins are regulatory proteins for cyclin-dependent kinases and
are differentially synthesized and degraded at specific points
during the cell cycle. Five major classes of mammalian cyclins
have been described (cyclin A-E). Cyclin C, D1-3 and E reach
their peak of synthesis and activity during the G, phase and regu-
late the transition fromGI to S-phase. Cyclins A and B1-2 achieve
their peaks during S- and G2 phases (Cordon-Cardo, 1995). Along
with otherresearchers, we could demonstrate that cyclin A expres-
sion closely correlates with the proportion of S-phase cells
measured by flow cytometry (Paterlini, 1995). Dutta et al (1995)
correlated the expression of several cyclins and found positive
correlations to the staining indices for other proliferation markers
(Ki-67; S-phase fraction).
In the present investigation, we found that cyclin A is indeed a
good prognostic indicator for patient survival. Patients with cyclin
A-positive NSCLC had significantly shorter survival times than
patients with cyclin A-negative carcinomas. Identical results were
obtained when the analysis was restricted to just those patients
with stage III tumours or to patients with lymph node involvement
at the time of surgery or to patients with epidermoid lung carci-
nomas. Furthermore, we could show that a significant correlation
exists between cyclin A and the response to doxorubicin in vitro.
Tumours with low proliferative activity were more frequently
resistant to doxorubicin.
In a further investigation, 20 adjacent normal human tissues
were analysed by means of immunohistochemistry for the expres-
sion of cyclin A. This protein could be detected in only a few
samples of normal tissue (data not shown). Cyclin A has been
reported to be also involved in the proliferation ofbenign regener-
ative livercells (Zindy et al, 1992). In contrast, Inohara and Kitano
(1994) could not find cyclin A in the cells ofnormal epidermis.
Estimating the proliferative activity ofa tumour is important for
tumour management and prognosis. Results from earlier studies
involving NSCLC and using flow cytometry showed that patients
whose tumours had a high proliferative activity had shorter
survival times than patients having carcinomas with a low prolifer-
ative activity (Volm et al, 1988). Our data indicate that cyclin A
may also be a good prognostic indicator for the survival of lung
cancer patients and for drug response. If these results are
confirmed for other tumour types, cyclin A might be added to the
other prognostic factors used to characterize subsets of patients
having an unfavourable outcome. It might be used to predict
therapeutic success and to plan follow-up strategies.
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